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Abstract
Background: Invasive diseases (ID) caused by Streptococcus pneumoniae (S. pneumoniae), Haemophilus influenzae
(H. influenzae), and Neisseria meningitidis are a major public health problem worldwide. Comprehensive data on the
burden of bacteremia and ID in Italy, including data based on molecular techniques, are needed.
Methods: We conducted a prospective, multi-centre, hospital-based study (GSK study identifier: 111334) to assess the
burden of bacteremia and ID among children less than five years old with a fever of 39 °C or greater. Study
participation involved a single medical examination, collection of blood for polymerase chain reaction (PCR) and blood
culture, and collection of an oropharyngeal swab for colonization analysis by PCR.
Results: Between May 2008 and June 2009, 4536 patients were screened, 944 were selected and 920 were enrolled in
the study. There were 225 clinical diagnoses of ID, 9.8 % (22) of which were bacteremic. A diagnosis of sepsis was
made for 38 cases, 5.3 % (2) of which were bacteremic. Among the 629 non-ID diagnoses, 1.6 % (10) were bacteremic.
Among the 34 bacteremic cases, the most common diagnoses were community-acquired pneumonia (15/34), pleural
effusion (4/34) and meningitis (4/34). S. pneumoniae was the most frequently detected bacteria among bacteremic
cases (29/34) followed by H. influenzae (3/34). Ninety percent (27/30) of bacteremic patients with oropharyngeal swab
results were colonized with the studied bacterial pathogens compared to 46.1 % (402/872) of non-bacteremic cases (p
< 0.001). PCV7 (7-valent pneumococcal conjugate vaccine) vaccination was reported for 55.9 % (19/34) of bacteremic
cases. S. pneumoniae serotypes were non-vaccine serotypes in children who had been vaccinated. Mean duration of
hospitalization was longer for bacteremic cases versus non-bacteremic cases (13.6 versus 5.8 days).
Conclusions: These results confirm that S. pneumoniae is one of the pathogens frequently responsible for invasive
disease.
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Background
Invasive diseases (ID) are considered any disease where
microorganisms are identified in the normally sterile body
fluids. Bacteremia may be due to predisposing risk factors
(sickle cell anemia, oncologic disease, immunodeficiency,
indwelling central catheter, etc.), definitive focal infec-
tion (pneumonia, meningitis, cellulites, etc.) or present
as occult bacteremia, i.e. the presence of pathogenic
bacteria in the blood of a well-appearing febrile child
without an identifiable focus of infection. Invasive dis-
eases (ID) caused by Streptococcus pneumoniae (S. pneu-
moniae), Haemophilus influenzae (H. influenzae), and
Neisseria meningitidis including pneumonia, bacteremia
and meningitis and other illnesses, are a major public
health problem worldwide. In Europe, estimated annual
invasive pneumococcal disease (IPD) incidence per 100,000
population has been reported in hospital-based studies
to range from 0.3 to 20.3, and varies by age, with the
highest incidence observed in children less than two
years of age [1]. Availability of pneumococcal vaccines
has led to substantial decreases in overall IPD in the
United States and Europe [2–4], and there is also evidence
of benefits for the unvaccinated population through herd
immunity [5]. Concerns about potential replacement of
vaccine serotypes with non-vaccine serotypes still need to
be addressed.
Knowledge of Italian epidemiologic features of bac-
teremia and ID relies on voluntary reporting and sending
strains to the national reference laboratory, therefore, the
true burden may be underestimated and under-reported
[6–8]. More comprehensive surveillance, supported by
molecular epidemiological analyses, is considered a prior-
ity among all the European countries by the European
Centre for Disease Control and Prevention.
We conducted a prospective, multi-centre, hospital-
based study to assess the burden of bacteremia and
ID, including cost of hospitalization, clinical severity,
causative agents and vaccination status, among chil-
dren less than five years of age with a fever of 39 °C or
greater. Additionally, oropharyngeal colonization by the
investigated bacteria and the estimated clinical expenses
due to bacteremia were examined.
Methods
Study objectives and definitions
The primary objective of the study was to assess the
incidence of bacteremia and invasive diseases (ID) in
children <5 years of age in pediatric hospitals in Italy.
Secondary objectives were to determine the clinical sever-
ity of bacteremia and describe concomitant contributing
clinical factors; to determine the rate of hospitalization
due to bacteremia; to identify the causative organisms
of bacteremia with a major interest in S. pneumoniae,
H. influenzae and Neisseria meningitidis and their
susceptibility to antimicrobial agents; to assess the rate of
IPD in patients previously vaccinated with pneumococcal
vaccine; to assess polymerase chain reaction (PCR) sensi-
tivity in diagnosis of bacteremia; to assess biological sam-
ples positive cultures or PCR according to subject’s
previous antibacterial treatment; to assess oropharyngeal
colonization by the investigated bacteria; to assess the inci-
dence of febrile illness in children <5 years of age; and to
estimate clinical management expenses due to bacteremia.
Children were enrolled in this prospective, hospital-
based study (GSK study identifier: 111334) at emergency
departments or inpatient clinics at participating pediatric
hospitals in Genova, Bari, Napoli, Roma, Firenze, Trieste,
Ancona, Novara and Milano from May 2008 to June 2009.
Sample size
The expected number of cases of children with fever of at
least 39 °C was estimated based on the hospital activity
reports over the previous three years. Sample size was
derived from the figures given by each participating centre
on the at-risk population (i.e. children <5 years of age with
fever ≥39 °C) attending their hospitals in a 12 month time-
frame. Assuming compliance to the study requirements
(i.e. informed consent of both parents, invasive proce-
dures, etc.) of 33 % from each centre, a mean number of
400 subjects per centre were expected for a total of nearly
4000 enrolled subjects.
Inclusion and exclusion criteria
Children were eligible if they were less than five years of
age, had a fever of at least 39 °C at enrolment or at
home with at least one measurement in the 12 h preced-
ing enrolment, and had been a resident in the district of
the hospital for at least the last three months. At home,
fever may have been measured by parents using any
method; at enrolment fever was measured for infants
under four weeks using an electronic thermometer in
the axilla, and for children four weeks to five years by an
electronic thermometer or chemical dot thermometer in
the axilla or an infrared tympanic thermometer. Children
with a presumptive diagnosis of gastroenteritis or a clin-
ical diagnosis of infectious exantherma were excluded
from the study. Informed consent was obtained from
each parent/guardian prior to performance of any study-
specific procedures.
Study recruitment and procedures
The study involved a single visit which included a medical
examination, collection of a blood sample for local bio-
chemistry and bacteriology (culture), and collection of a
blood and oropharyngeal sample for invasive disease or
colonization to be sent for PCR to the study laboratory.
Data on demographics, medical history, vaccination status
and previous antibiotic treatment and current fever
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treatment were also collected at the visit. A log book with
aggregated number of fever and ID cases presenting to the
centre, regardless of participation status in the study, was
maintained at each study centre.
Bacteremic cases were defined as subjects fulfilling
inclusion and exclusion criteria with a blood sample
positive for bacteria either by PCR or by blood culture.
A case was considered non-bacteremic if the PCR or
blood culture testing was negative for the 3 bacteria that
were tested. Bacteremia predisposing factors included
sickle cell anemia, oncologic disease, immunodeficiency,
indwelling central catheter or shunts, agranulocitosis,
aplastic anemia, arteritis, renal transplant, congenital heart
abnormalities, congestive heart failure, cystic fibrosis,
human immunodeficiency virus (HIV), Lyme disease,
Kawasaki disease and nephritic syndrome.
Diagnoses of focal infections such as community-
acquired pneumonia (CAP), pleural effusion, meningitis,
cellulites, lymphadenitis, otitis media, or pharyngitis were
made on the basis of available diagnostic findings (such as
X-rays or cerebrospinal fluid findings). The same criterion
was applied for systemic infections (sepsis). A patient could
receive more than one diagnosis. The clinical diagnosis
made by the investigator of community-acquired was cate-
gorized as either a diagnosis of invasive disease or as a diag-
nosis of non-invasive disease. Pneumonia, pleural effusion,
meningitis and sepsis were considered primary clinical diag-
noses suggestive of invasive disease. Although sepsis was
considered invasive, it was also examined in a separate
category. Other diagnoses such as cellulites, lymphadenitis,
otitis media and pharyngitis were considered non-invasive.
Laboratory analysis
The presence of S. pneumoniae, Neisseiria meningitidis
or H. influenzae type b (Hib) DNA in biological samples
and isolates was evaluated by Realtime PCR (RT-PCR)
using the EuSep screen kit (Eurospital, Trieste, Italy)
according to manufacturer instructions. The cycle thresh-
old (CT) value is the PCR cycle number (out of 45) at
which the measured fluorescent signal exceeds a calcu-
lated background threshold identifying amplification of
the target sequence. If no increase in fluorescent signal is
observed after 45 cycles, the sample is assumed to be
negative. The presence of Haemophilus different from Hib
was evaluated by a home-made method, using bexA and
ompP2 genes as targets and previously published primers
and probes (REfX). The presence of S. pneumoniae DNA
was confirmed by the amplification of CpsA gene in
end-point PCR as previously reported [9, 10] and briefly
described in the next paragraph. Only samples positive for
both lytA gene in RT-PCR and CpsA in end-point PCR
were included in pneumococcal serotyping analysis.
For pneumococcal serotyping, RT-PCR was performed
in 25 μL reaction volumes containing 2x TaqMan
Universal Master Mix (Applied Biosystem, Foster City,
CA, USA); primers and JOE labeled probes were used at
a concentration of 400 nM; FAM labeled probes at a con-
centration of 200 nM. Six μl of DNA extract was used for
each reaction. All reactions were performed in triplicate.
Negative controls (both blood samples from healthy con-
trols and sterile water samples) and positive controls
(blood samples or cerebrospinal fluid samples known to
be positive for S. pneumoniae both by cultural and mo-
lecular methods) were included in every run. DNA was
amplified in an ABI 7500 sequence detection system
(Applied Biosystem, Foster City, CA, USA) using, for all
the primers couples, the same cycling parameters as
follows: 50 °C for two minutes for UNG digestion, 95 °C
for 10 min followed by 45 cycles of a two-stage
temperature profile of 95 °C for 15 s and 60 °C for one mi-
nute. If no increase in fluorescent signal was observed
after 45 cycles for any of the primer/probe set, the sample
was assumed to be negative with the serotype specific
primers and was reported as non-typeable.
For culture purposes, 4–6 ml of blood samples (up
to three sets) were taken at the fever peak and imme-
diately sent to the local laboratory; procedures established
by each hospital for these tests were used, as described
previously [11].
Health economics
Economic data relevant to expenses due to bacteremia were
also collected from a subset of children in order to examine
and estimate the associated clinical management expenses.
Statistical analysis
Demographic and clinical characteristics were tabulated
by means of descriptive statistics. Medical history, other
relevant clinical information and PCR results were pre-
sented by means of frequency and percentage distribution.
Descriptive statistics were calculated based on health eco-
nomic endpoints. Fisher’s Exact test was used for statis-
tical comparison of categorical variables.
Statistical analysis was conducted using SAS version
9.2 (SAS Institute, Cary, NC, USA). The study protocol
was reviewed and approved by both local and national
institutional review boards. The Institutional Review
Board (IRB) of the Azienda ospedaliero-universitaria
“Maggiore della Carità” in Novara (Principal Investiga-
tor: Prof. Gianni Bona) first approved the study, then all
the IRBs of the participating centers were notified ac-
cording to the regulatory laws at the time.
Results
A total of 4536 patients were screened and 944 subjects
with high fever were selected for study inclusion between
May 2008 and June 2009. The majority of screening
failures had a missing reason or ‘other’ reason for non-
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enrolment (Fig. 1). After exclusion of eight children due to
age greater than five years, two due to a lack of an
analyzed blood sample, thirteen due to not being a resi-
dent for at least three months and one patient for whom
only demographic data were collected, 920 children were
enrolled in the study. The mean age at enrolment was
23.1 months (range 0–59), and 58 % (529/920) of the
children were male. The age group with the greatest pro-
portion of enrolled children was the one year of age group
(Table 1, Fig. 2). Among the 814 children with a non-
rectal temperature measurement from home, the mean
temperature was 39.5 °C; among the 97 children with
a rectal temperature home measurement the mean
temperature was 39.7 °C. Home temperature was not
recorded in nine cases. The mean temperature at enrol-
ment was 38.7 °C (range 34.7-41.1), and 73 % (672/920) of
children with fever were hospitalized. At least one predis-
posing factor was present for 1.4 % (13/920) of children
(e.g. oncologic disease, immunodeficiency, intracatheter or
central shunt, congenital cardiac anomaly). Thirty-seven
percent (339/920) of children reported having received at
least one dose of the 7-valent pneumococcal conjugate
vaccine (PCV7; Prevenar, Pfizer/Wyeth). Antibiotic use
before enrolment was reported for 42 % (389/920) of
children, and antibiotic use for greater than 24 h was
reported for 29 % (262/920) of children. Antipyretic treat-
ment was reported for 88 % (812/920) of children. Sys-
temic inflammatory response syndrome (SIRS) [12] was
present in 55 % (507/920) of study patients.
A total of 225 children had a clinical diagnosis of ID,
38 had a diagnosis of sepsis, and 629 had a clinical diag-
nosis of non-invasive disease (Fig. 1). Thirty-four of the
920 children (3.7 %) were considered bacteremic cases,
having at least one positive sample, detected either by
molecular assessment (PCR), culture, or both. Among
children with a clinical diagnosis of ID, 9.8 % (22/225)
were bacteremic and among children with sepsis, 5.3 %
(2/38) were bacteremic, whereas 1.6 % (10/629) of chil-
dren with a clinical diagnosis of non-invasive disease
were bacteremic. PCR was carried out on all the sam-
ples, reaching 91 % (31/34) positivity. Culture analysis
was performed on 25/34 samples; 36 % (9/25) were posi-
tive. Of note, one of the culture-positive samples yielded
Escherichia Coli, which was not targeted for detection
with the PCR. On samples tested simultaneously with
both RT-PCR and cultures, 72 % of cases were diagnosed
by RT-PCR alone. The overall underestimation factor
associated with the use of culture only was 2.53.
The most common diagnosis was CAP, diagnosed in
44.1 % (15/34) of bacteremic cases and 22.5 % (199/886)
of non-bacteremic cases (p = 0.003) (Table 1). Pleural
effusion was diagnosed in 11.8 % (4/34) of bacteremic
and 0.5 % (4/886) of non-bacteremic cases (p < 0.0001)
and in 4/15 of CAP (26.7 %). Meningitis was diagnosed
in 11.8 % (4/34) of bacteremic and 0.2 % (2/886) of non-
bacteremic children (p < 0.0001).
S. pneumoniae was the most frequently detected bac-
teria among bacteremic cases, accounting for 85.3 %
Fig. 1 Flow chart for study inclusion and prevalence of invasive disease and bacteremia. Patients could have more than one diagnosis
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(29/34) of cases. H. influenzae was detected in three
cases (2 non-typeable and 1 capsulated), Escherichia Coli
in one, and Neisseria meningitidis in one (Table 2). The
most commonly detected S. pneumoniae serotype was
19A, detected in four cases. Among the 15 cases of CAP,
14 were due to S. pneumoniae, with three due to sero-
type 3 and three due to serotype 14. All four cases of
pleural effusion were due to S. pneumoniae, while three
of the four cases of meningitis were due to S. pneumo-
niae with the remaining case was due to Neisseria
meningitidis. Serotypes are shown in Table 2. Among en-
rolled cases with oropharyngeal swab results available,
47.6 % (429/902) were colonized by a various mix of the
studied bacterial pathogens; 90 % (27/30) of bacteremic
cases were colonized compared to 46.1 % (402/872) of
non-bacteremic cases (p < 0.001).
From parents’ recollection, PCV7 vaccination was re-
ported for 62.1 % (18/29) of bacteremic cases caused by
S. pneumoniae. Six of the 18 S. pneumoniae cases report-
edly received three doses of the vaccine (cases were due
to serotypes 3, 14, 18, 19A and non-typeable (two)). As
for the case due to serotype 18, the laboratory analysis
method used could not differentiate serotype 18B (non-
vaccine serotype) from 18C (vaccine serotype). Another six
reportedly received two doses (cases were due to serotypes
1 (two), 7F-7A, 14, non-typeable and one missing). As
Table 1 Characteristics and clinical diagnoses of bacteremic and non-bacteremic cases
Bacteremic (N = 34) Non-bacteremic (N = 886) All cases (N = 920)
Age
< 1 year 9 (26.5 %) 242 (27.3 %) 251 (27.3 %)
1 year 7 (20.6 %) 273 (30.8 %) 280 (30.4 %)
2 years 8 (23.5 %) 159 (17.9 %) 167 (18.2 %)
3 years 7 (20.6 %) 131 (14.8 %) 138 (15.0 %)
4 years 3 (8.8 %) 81 (9.1 %) 84 (9.1 %)
Prior antibiotic treatment
No 17 (50.0 %) 481 (54.3 %) 498 (54.1 %)
Yes 16 (47.1 %) 373 (42.1 %) 389 (42.3 %)
Unknown 1 (2.9 %) 32 (3.6 %) 33 (3.6 %)
Prior antipyretic treatment
No 4 (11.8 %) 79 (8.9 %) 83 (9.0 %)
Yes 30 (88.2 %) 782 (88.3 %) 812 (88.3 %)
Unknown 0 25 (2.8 %) 25 (2.7 %)
Temperature at enrolment (axillary)
< 39 °C 18 (52.9 %) 452 (51.0 %) 470 (51.1 %)
39–39.4 °C 10 (29.4 %) 239 (27.0 %) 249 (27.1 %)
39.5–39.9 °C 6 (17.6 %) 130 (14.7 %) 136 (14.8 %)
≥ 40 °C 0 63 (7.1 %) 63 (6.8 %)
Missing 0 2 (0.2 %) 2 (0.2 %)
Clinical diagnosis of invasive diseasea
Community-acquired pneumonia 15 (44.1 %) 199 (22.5 %) 214 (23.3 %)
Pleural effusion 4 (11.8 %) 4 (0.5 %) 8 (0.9 %)
Meningitis 4 (11.8 %) 2 (0.2 %) 6 (0.7 %)
Sepsis 2 (5.9 %) 36 (4.1 %) 38 (4.1 %)
Clinical diagnosis of non-invasive diseasea
Cellulites 1 (2.9 %) 5 (0.6 %) 6 (0.7 %)
Lymphoadenitis 0 12 (1.4 %) 12 (1.3 %)
Otitis media 3 (8.8 %) 38 (4.3 %) 41 (4.5 %)
Pharyngitis 0 27 (3.0 %) 27 (2.9 %)
Genitourinary infection 1 (2.9 %) 45 (5.1 %) 46 (5.0 %)
Other infection 5 (14.7 %) 500 (56.4 %) 505 (54.9 %)
aCases could have more than one primary and/or secondary diagnosis
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for the IPD caused by serotype 14, the two doses had
been administered at the fourth and seventh month of
life, while the dose that is recommended in the second
year of life had not been administered. The remaining
six reportedly received one dose (cases were due to se-
rotypes 3, 7F-7A, 19F (two) and non-typeable (two)).
The health economics study included 174 of the en-
rolled children. The mean duration of hospitalization was
6.47 days (range 1–38) and was longer for bacteremic
(13.6 days, standard deviation 9.6) than non-bacteremic
(5.8 days, standard deviation 4.0) cases. The mean number
of working hours lost was 28.5 (standard deviation 32.4),
and was higher for the two bacteremic cases with data
available (108, standard deviation 45.3) than for the 75
non-bacteremic cases with data available (26.3, standard
deviation 29.6). The mean costs sustained by the family
were 107.4 euro (standard deviation 347.6), with a mean
cost of 1300 euro (standard deviation 1838) for the two
Fig. 2 Distribution of confirmed diagnoses by age among the enrolled children





















Escherichia coli 1 (2.9 %) 1 (2.9 %)
Neisseria
meningitidis C
1 (2.9 %) 1 (2.9 %)
Haemophilus
influenzae (total)
1 (2.9 %) 2 (5.9 %) 3 (8.8 %)
Non-typeable 1 (2.9 %) 1 (2.9 %) 2 (5.9 %)
Serotype missing 1 (2.9 %) 1 (2.9 %)
Streptococcus
pneumoniae (total)
14 (41.2 %) 4 (11.8 %) 3 (8.8 %) 2 (5.9 %) 1 (2.9 %) 3 (8.8 %) 3 (8.8 %) 29 (85.3 %)
Serotype 1 2 (5.9 %) 2 (5.9 %)
Serotype 3a 3 (8.8 %) 1 (2.9 %) 3 (8.8 %)
Serotype 5 1 (2.9 %) 1 (2.9 %) 2 (5.9 %)
Serotype 6A 1 (2.9 %) 1 (2.9 %)
Serotype 7F-7A 1 (2.9 %) 1 (2.9 %) 2 (5.9 %)
Serotype 14 3 (8.8 %) 3 (8.8 %)
Serotype 18 1 (2.9 %) 1 (2.9 %)
Serotype 19A 1 (2.9 %) 1 (2.9 %) 1 (2.9 %) 1 (2.9 %) 4 (11.8 %)
Serotype 19F 1 (2.9 %) 1 (2.9 %) 2 (5.9 %)
Serotype 23F 1 (2.9 %) 1 (2.9 %)
Non-typable 2 (5.9 %) 1 (2.9 %) 1 (2.9 %) 1 (2.9 %) 5 (14.7 %)
Serotype missing 1 (2.9 %) 1 (2.9 %) 1 (2.9 %) 3 (8.8 %)
aOne patient had community-acquired pneumonia and pleural effusion with Streptococcus pneumoniae 3
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bacteremic cases and 81.2 euro (standard deviation 231.6)
for the 91 non-bacteremic cases. As there were only two
bacteremic cases with data available on working hours lost
and medical costs, comparisons between bacteremic and
non-bacteremic cases could not be made.
Discussion
This study provides much needed information on the
burden of bacteremia and ID among children less than
five years of age with fever ≥39 °C seeking hospital care
in Italy. Thirty-four bacteremic cases out of 920 children
with high fever were detected through blood assays;
blood analysis (molecular or cultural method) is import-
ant for bacteremia diagnosis and should be implemented
in children represented by our study population. The
proportion of children with bacteremia is likely an under-
estimation of what is expected in the entire population,
since not all patients present at the hospital, and not all
presenting patients were enrolled in the study.
CAP and upper respiratory tract infections were the
most common infections and reasons for hospitaliza-
tions. More than 50 % of enrolled children presented with
SIRS (used to measure severity of children seen in hos-
pital), which confirms that this population is clinically
relevant. A high proportion of children with fever were
hospitalized, however, it should be noted that children
presenting at the hospital with fever but with a good
clinical profiles would not have been hospitalized and a
blood sample would not be drawn, making the child
ineligible for the study. Therefore, this figure is likely
an overestimation.
S. pneumoniae was the most commonly detected (85 %)
bacteria under study in bacteremic patients, followed by
H. influenzae (9 %). Several of the bacteremic cases caused
by S. pneumoniae, including cases due to PCV7 serotypes,
reported having received at least one PCV7 dose. This
finding was unexpected, and more detailed information
on the timing of vaccination and underlying health of
these children are necessary to better understand this
finding. Two out of three H. influenzae cases were due to
non-typeable H. influenzae, an emerging pathogen which
causes invasive and respiratory infections; a preventive
strategy should include as many pneumococcal serotypes
as possible and hopefully, in the future, other bacteria
causing bacteremia and ID.
Use of the newer molecular techniques for detection of
bacteremia is a recent development, and there are very
few studies on bacteremia in children in Italy using these
techniques [10, 13]. Molecular methods for diagnosing
and serotyping bacteremia, such as PCR, do not require
viable bacteria, require smaller sample volumes than
more traditional blood culture methods, and appear to be
more sensitive [10, 11, 13], allowing for a more accurate
assessment of the burden of bacteremia. A highly sensitive
technique is particularly necessary in the setting of anti-
biotic use, such as in our study population, where 42 % of
children had been exposed to antibiotics. Our results
support the higher sensitivity of the molecular techniques
versus the blood culture techniques.
Costs generated by a case of bacteremia can be con-
sistent both in the National Healthcare System and in
the families’ perspective, with an estimated average
direct medical cost of 3306 euro for each hospital-
ized case (range 511–19,418) based on the estimated daily
hospitalization cost of 511 euro [14]. There is a high social
cost of more than 100 euro/family on average, and hours
lost from work, data which highlight the burden of disease
on families of affected children.
A primary limitation of this study was the lower than
expected sample size. Despite efforts to take the crowded
nature and often overloaded healthcare personnel of the
emergency departments into consideration in the study
design, the target enrolment was still not met. The study
aimed to recruit 4000 patients, but ultimately 920 were
enrolled. The limited availability of data on reasons for
non-enrolment makes it difficult to determine the primary
obstacles to meeting target enrolment.
Conclusions
S. pneumoniae was confirmed to be one of the more
frequent pathogen responsible for bacteremia, with over
80 % of cases attributable to the pathogen. The study
confirms the higher sensitivity of molecular versus cul-
tural techniques for detecting bacteremia. Overall the
study contributes to our understanding of the burden of
IPD among Italian children, and provides important data
on bacteremia and ID associated with high fever in this
population. The study also documents the estimate of
the costs associated with bacteremia and sustained by
the families. Prevention of bacteremia by means of
vaccination is thus warranted.
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